Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus
Abstract
Oncolytic adenoviruses are anticancer agents that replicate within tumors and spread to uninfected tumor cells, amplifying the anticancer effect of initial transduction. We tested whether coating the viral particle with polyethylene glycol (PEG) could reduce transduction of hepatocytes and hepatotoxicity after systemic (intravenous) administration of oncolytic adenovirus serotype 5 (Ad5). Conjugating Ad5 with high molecular weight 20-kDa PEG but not with 5-kDa PEG reduced hepatocyte transduction and hepatotoxicity after intravenous injection. PEGylation with 20-kDa PEG was as efficient at detargeting adenovirus from Kupffer cells and hepatocytes as virus predosing and warfarin. Bioluminescence imaging of virus distribution in two xenograft tumor models in nude mice demonstrated that PEGylation with 20-kDa PEG reduced liver infection 19- to 90-fold. Tumor transduction levels were similar for vectors PEGylated with 20-kDa PEG and unPEGylated vectors. Anticancer efficacy after a single intravenous injection was retained at the level of unmodified vector in large established prostate carcinoma xenografts, resulting in complete elimination of tumors in all animals and long-term tumor-free survival. Anticancer efficacy after a single intravenous injection was increased in large established hepatocellular carcinoma xenografts, resulting in significant prolongation of survival as compared with unmodified vector. The increase in efficacy was comparable to that obtained with predosing and warfarin pretreatment, significantly extending the median of survival. Shielding adenovirus with 20-kDa PEG may be a useful approach to improve the therapeutic window of oncolytic adenovirus after systemic delivery to primary and metastatic tumor sites.
Get full access to this article
View all available purchase options and get full access to this article.
References
Alemany R.2007. Cancer selective adenovirusesMol. Aspects Med.2842-58. Alemany, R. (2007). Cancer selective adenoviruses. Mol. Aspects Med. 28, 42–58.
Alemany R.Suzuki K.Curiel D.T.2000. Blood clearance rates of adenovirus type 5 in miceJ. Gen. Virol.812605-2609. Alemany, R., Suzuki, K., and Curiel, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605–2609.
Barton K.N.Paielli D.Zhang Y.Koul S.Brown S.L.Lu M.Seely J.Kim J.H.Freytag S.O.2006. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicityMol. Ther.13347-356. Barton, K.N., Paielli, D., Zhang, Y., Koul, S., Brown, S.L., Lu, M., Seely, J., Kim, J.H., and Freytag, S.O. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 13, 347–356.
Carlisle R.C.Di Y.Cerny A.M.Sonnen A.F.Sim R.B.Green N.K.Subr V.Ulbrich K.Gilbert R.J.Fisher K.D.Finberg R.W.Seymour L.W.2009. Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus–adenovirus receptor and complement receptor 1Blood1131909-1918. Carlisle, R.C., Di, Y., Cerny, A.M., Sonnen, A.F., Sim, R.B., Green, N.K., Subr, V., Ulbrich, K., Gilbert, R.J., Fisher, K.D., Finberg, R.W., and Seymour, L.W. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus–adenovirus receptor and complement receptor 1. Blood 113, 1909–1918.
Cascallo M.Alonso M.M.Rojas J.J.Perez-Gimenez A.Fueyo J.Alemany R.2007. Systemic toxicity–efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathwayMol. Ther.151607-1615. Cascallo, M., Alonso, M.M., Rojas, J.J., Perez-Gimenez, A., Fueyo, J., and Alemany, R. (2007). Systemic toxicity–efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther. 15, 1607–1615.
Cattaneo R.Miest T.Shashkova E.V.Barry M.A.2008. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shieldedNat. Rev. Microbiol.6529-540. Cattaneo, R., Miest, T., Shashkova, E.V., and Barry, M.A. (2008). Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat. Rev. Microbiol. 6, 529–540.
Croyle M.A.Chirmule N.Zhang Y.Wilson J.M.2001. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lungJ. Virol.754792-4801. Croyle, M.A., Chirmule, N., Zhang, Y., and Wilson, J.M. (2001). “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792–4801.
Croyle M.A.Le H.T.Linse K.D.Cerullo V.Toietta G.Beaudet A.Pastore L.2005. PEGylated helper-dependent adenoviral vectors: Highly efficient vectors with an enhanced safety profileGene Ther.12579-587. Croyle, M.A., Le, H.T., Linse, K.D., Cerullo, V., Toietta, G., Beaudet, A., and Pastore, L. (2005). PEGylated helper-dependent adenoviral vectors: Highly efficient vectors with an enhanced safety profile. Gene Ther. 12, 579–587.
Dhar D.Spencer J.F.Toth K.Wold W.S.2009. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamstersJ. Virol.832130-2139. Dhar, D., Spencer, J.F., Toth, K., and Wold, W.S. (2009). Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J. Virol. 83, 2130–2139.
Di Paolo N.C.van Rooijen N.Shayakhmetov D.M.2009. Redundant and synergistic mechanisms control the sequestration of blood-borne adenovirus in the liverMol. Ther.17675-684. Di Paolo, N.C., van Rooijen, N., and Shayakhmetov, D.M. (2009). Redundant and synergistic mechanisms control the sequestration of blood-borne adenovirus in the liver. Mol. Ther. 17, 675–684.
Doronin K.Toth K.Kuppuswamy M.Ward P.Tollefson A.E.Wold W.S.2000. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death proteinJ. Virol.746147-6155. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A.E., and Wold, W.S. (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147–6155.
Doronin K.Kuppuswamy M.Toth K.Tollefson A.E.Krajcsi P.Krougliak V.Wold W.S.2001. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapyJ. Virol.753314-3324. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V., and Wold, W.S. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75, 3314–3324.
Doronin K.Toth K.Kuppuswamy M.Krajcsi P.Tollefson A.E.Wold W.S.2003. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirusVirology305378-387. Doronin, K., Toth, K., Kuppuswamy, M., Krajcsi, P., Tollefson, A.E., and Wold, W.S. (2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378–387.
Duncan S.J.Gordon F.C.Gregory D.W.McPhie J.L.Postlethwaite R.White R.Willcox H.N.1978. Infection of mouse liver by human adenovirus type 5J. Gen. Virol.4045-61. Duncan, S.J., Gordon, F.C., Gregory, D.W., McPhie, J.L., Postlethwaite, R., White, R., and Willcox, H.N. (1978). Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40, 45–61.
Fishburn C.S.2008. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeuticsJ. Pharm. Sci.974167-4183. Fishburn, C.S. (2008). The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97, 4167–4183.
Gao J.Q.Eto Y.Yoshioka Y.Sekiguchi F.Kurachi S.Morishige T.Yao X.Watanabe H.Asavatanabodee R.Sakurai F.Mizuguchi H.Okada Y.Mukai Y.Tsutsumi Y.Mayumi T.Okada N.Nakagawa S.2007. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administrationJ. Control. Release122102-110. Gao, J.Q., Eto, Y., Yoshioka, Y., Sekiguchi, F., Kurachi, S., Morishige, T., Yao, X., Watanabe, H., Asavatanabodee, R., Sakurai, F., Mizuguchi, H., Okada, Y., Mukai, Y., Tsutsumi, Y., Mayumi, T., Okada, N., and Nakagawa, S. (2007). Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control. Release 122, 102–110.
Garber K.2006. China approves world's first oncolytic virus therapy for cancer treatmentJ. Natl. Cancer Inst.98298-300. Garber, K. (2006). China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298–300.
Harris J.M.Chess R.B.2003. Effect of pegylation on pharmaceuticalsNat. Rev. Drug Discov.2214-221. Harris, J.M., and Chess, R.B. (2003). Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214–221.
Heideman D.A.Steenbergen R.D.van Der T.J.Scheffner M.Alemany R.Gerritsen W.R.Meijer C.J.Snijders P.J.van Beusechem V.W.2005. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancerMol. Ther.121083-1090. Heideman, D.A., Steenbergen, R.D., van Der, T.J., Scheffner, M., Alemany, R., Gerritsen, W.R., Meijer, C.J., Snijders, P.J., and van Beusechem, V.W. (2005). Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol. Ther. 12, 1083–1090.
Hermiston T.2006. A demand for next-generation oncolytic adenovirusesCurr. Opin. Mol. Ther.8322-330. Hermiston, T. (2006). A demand for next-generation oncolytic adenoviruses. Curr. Opin. Mol. Ther. 8, 322–330.
Hofherr S.E.Shashkova E.V.Weaver E.A.Khare R.Barry M.A.2008. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expressionMol. Ther.161276-1282. Hofherr, S.E., Shashkova, E.V., Weaver, E.A., Khare, R., and Barry, M.A. (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16, 1276–1282.
Jakubczak J.L.Ryan P.Gorziglia M.Clarke L.Hawkins L.K.Hay C.Huang Y.Kaloss M.Marinov A.Phipps S.Pinkstaff A.Shirley P.Skripchenko Y.Stewart D.Forry-Schaudies S.Hallenbeck P.L.2003. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: Dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacyCancer Res.631490-1499. Jakubczak, J.L., Ryan, P., Gorziglia, M., Clarke, L., Hawkins, L.K., Hay, C., Huang, Y., Kaloss, M., Marinov, A., Phipps, S., Pinkstaff, A., Shirley, P., Skripchenko, Y., Stewart, D., Forry-Schaudies, S., and Hallenbeck, P.L. (2003). An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: Dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 63, 1490–1499.
Kalyuzhniy O.Di Paolo N.C.Silvestry M.Hofherr S.E.Barry M.A.Stewart P.L.Shayakhmetov D.M.2008. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivoProc. Natl. Acad. Sci. U.S.A.1055483-5488. Kalyuzhniy, O., Di Paolo, N.C., Silvestry, M., Hofherr, S.E., Barry, M.A., Stewart, P.L., and Shayakhmetov, D.M. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483–5488.
Kirn D.2001. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?Gene Ther.889-98. Kirn, D. (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 8, 89–98.
Kojaoghlanian T.Flomenberg P.Horwitz M.S.2003. The impact of adenovirus infection on the immunocompromised hostRev. Med. Virol.13155-171. Kojaoghlanian, T., Flomenberg, P., and Horwitz, M.S. (2003). The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 13, 155–171.
Kreppel F.Kochanek S.2008. Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guideMol. Ther.1616-29. Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide. Mol. Ther. 16, 16–29.
Liu Q.Zaiss A.K.Colarusso P.Patel K.Haljan G.Wickham T.J.Muruve D.A.2003. The role of capsid–endothelial interactions in the innate immune response to adenovirus vectorsHum. Gene Ther.14627-643. Liu, Q., Zaiss, A.K., Colarusso, P., Patel, K., Haljan, G., Wickham, T.J., and Muruve, D.A. (2003). The role of capsid–endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 14, 627–643.
Liu T.C.Galanis E.Kirn D.2007. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progressNat. Clin. Pract. Oncol.4101-117. Liu, T.C., Galanis, E., and Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101–117.
Liu T.C.Thorne S.H.Kirn D.H.2008. Oncolytic adenoviruses for cancer gene therapyMethods Mol. Biol.433243-258. Liu, T.C., Thorne, S.H., and Kirn, D.H. (2008). Oncolytic adenoviruses for cancer gene therapy. Methods Mol. Biol. 433, 243–258.
Lohr F.Huang Q.Hu K.Dewhirst M.W.Li C.Y.2001. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectorsClin. Cancer Res.73625-3628. Lohr, F., Huang, Q., Hu, K., Dewhirst, M.W., and Li, C.Y. (2001). Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin. Cancer Res. 7, 3625–3628.
Luo J.Xia Q.Zhang R.Lv C.Zhang W.Wang Y.Cui Q.Liu L.Cai R.Qian C.2008. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 geneClin. Cancer Res.142450-2457. Luo, J., Xia, Q., Zhang, R., Lv, C., Zhang, W., Wang, Y., Cui, Q., Liu, L., Cai, R., and Qian, C. (2008). Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin. Cancer Res. 14, 2450–2457.
Mok H.Palmer D.J.Ng P.Barry M.A.2005. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responsesMol. Ther.1166-79. Mok, H., Palmer, D.J., Ng, P., and Barry, M.A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66–79.
Morrison J.Briggs S.S.Green N.Fisher K.Subr V.Ulbrich K.Kehoe S.Seymour L.W.2008. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptorMol. Ther.16244-251. Morrison, J., Briggs, S.S., Green, N., Fisher, K., Subr, V., Ulbrich, K., Kehoe, S., and Seymour, L.W. (2008). Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 16, 244–251.
Nemunaitis J.Cunningham C.Buchanan A.Blackburn A.Edelman G.Maples P.Netto G.Tong A.Randlev B.Olson S.Kirn D.2001. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activityGene Ther.8746-759. Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., and Kirn, D. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 8, 746–759.
O'Riordan C.R.Lachapelle A.Delgado C.Parkes V.Wadsworth S.C.Smith A.E.Francis G.E.1999. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivoHum. Gene Ther.101349-1358. O'Riordan, C.R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S.C., Smith, A.E., and Francis, G.E. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349–1358.
Ogawara K.Rots M.G.Kok R.J.Moorlag H.E.van Loenen A.M.Meijer D.K.Haisma H.J.Molema G.2004. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivoHum. Gene Ther.15433-443. Ogawara, K., Rots, M.G., Kok, R.J., Moorlag, H.E., van Loenen, A.M., Meijer, D.K., Haisma, H.J., and Molema, G. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15, 433–443.
Parker A.L.Waddington S.N.Nicol C.G.Shayakhmetov D.M.Buckley S.M.Denby L.Kemball-Cook G.Ni S.Lieber A.McVey J.H.Nicklin S.A.Baker A.H.2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytesBlood1082554-2561. Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J.H., Nicklin, S.A., and Baker, A.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554–2561.
Post D.E.Sandberg E.M.Kyle M.M.Devi N.S.Brat D.J.Xu Z.Tighiouart M.van Meir E.G.2007. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4Cancer Res.676872-6881. Post, D.E., Sandberg, E.M., Kyle, M.M., Devi, N.S., Brat, D.J., Xu, Z., Tighiouart, M., and van Meir, E.G. (2007). Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 67, 6872–6881.
Reid T.Warren R.Kirn D.2002. Intravascular adenoviral agents in cancer patients: Lessons from clinical trialsCancer Gene Ther.9979-986. Reid, T., Warren, R., and Kirn, D. (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther. 9, 979–986.
Ryan S.M.Mantovani G.Wang X.Haddleton D.M.Brayden D.J.2008. Advances in PEGylation of important biotech molecules: Delivery aspectsExpert Opin. Drug Deliv.5371-383. Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M., and Brayden, D.J. (2008). Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin. Drug Deliv. 5, 371–383.
Sarkar D.Su Z.Z.Vozhilla N.Park E.S.Gupta P.Fisher P.B.2005. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude miceProc. Natl. Acad. Sci. U.S.A.10214034-14039. Sarkar, D., Su, Z.Z., Vozhilla, N., Park, E.S., Gupta, P., and Fisher, P.B. (2005). Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc. Natl. Acad. Sci. U.S.A. 102, 14034–14039.
Sauthoff H.Hu J.Maca C.Goldman M.Heitner S.Yee H.Pipiya T.Rom W.N.Hay J.G.2003. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time pointsHum. Gene Ther.14425-433. Sauthoff, H., Hu, J., Maca, C., Goldman, M., Heitner, S., Yee, H., Pipiya, T., Rom, W.N., and Hay, J.G. (2003). Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points. Hum. Gene Ther. 14, 425–433.
Schepelmann S.Ogilvie L.M.Hedley D.Friedlos F.Martin J.Scanlon I.Chen P.Marais R.Springer C.J.2007. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2Cancer Res.674949-4955. Schepelmann, S., Ogilvie, L.M., Hedley, D., Friedlos, F., Martin, J., Scanlon, I., Chen, P., Marais, R., and Springer, C.J. (2007). Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 67, 4949–4955.
Shashkova E.V.Spencer J.F.Wold W.S.Doronin K.2007. Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirusMol. Ther.15598-607. Shashkova, E.V., Spencer, J.F., Wold, W.S., and Doronin, K. (2007). Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15, 598–607.
Shashkova E.V.Doronin K.Senac J.S.Barry M.A.2008a. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirusCancer Res.685896-5904. Shashkova, E.V., Doronin, K., Senac, J.S., and Barry, M.A. (2008a). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res. 68, 5896–5904.
Shashkova E.V.Kuppuswamy M.N.Wold W.S.Doronin K.2008b. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAILCancer Gene Ther.1561-72. Shashkova, E.V., Kuppuswamy, M.N., Wold, W.S., and Doronin, K. (2008b). Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61–72.
Shayakhmetov D.M.Eberly A.M.Li Z.Y.Lieber A.2005. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobsJ. Virol.791053-1061. Shayakhmetov, D.M., Eberly, A.M., Li, Z.Y., and Lieber, A. (2005). Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J. Virol. 79, 1053–1061.
Small E.J.Carducci M.A.Burke J.M.Rodriguez R.Fong L.Van Ummersen L.Yu D.C.Aimi J.Ando D.Working P.Kirn D.Wilding G.2006. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerMol. Ther.14107-117. Small, E.J., Carducci, M.A., Burke, J.M., Rodriguez, R., Fong, L., Van Ummersen, L., Yu, D.C., Aimi, J., Ando, D., Working, P., Kirn, D., and Wilding, G. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14, 107–117.
Snoeys J.Lievens J.Wisse E.Jacobs F.Duimel H.Collen D.Frederik P.de Geest B.2007. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestraeGene Ther.14604-612. Snoeys, J., Lievens, J., Wisse, E., Jacobs, F., Duimel, H., Collen, D., Frederik, P., and de Geest, B. (2007). Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther. 14, 604–612.
Sova P.Ren X.W.Ni S.Bernt K.M.Mi J.Kiviat N.Lieber A.2004. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastasesMol. Ther.9496-509. Sova, P., Ren, X.W., Ni, S., Bernt, K.M., Mi, J., Kiviat, N., and Lieber, A. (2004). A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 9, 496–509.
Su C.Peng L.Sham J.Wang X.Zhang Q.Chua D.Liu C.Cui Z.Xue H.Wu H.Yang Q.Zhang B.Liu X.Wu M.Qian Q.2006. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent miceMol. Ther.13918-927. Su, C., Peng, L., Sham, J., Wang, X., Zhang, Q., Chua, D., Liu, C., Cui, Z., Xue, H., Wu, H., Yang, Q., Zhang, B., Liu, X., Wu, M., and Qian, Q. (2006). Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 13, 918–927.
Tollefson A.E.Scaria A.Hermiston T.W.Ryerse J.S.Wold L.J.Wold W.S.1996. The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cellsJ. Virol.702296-2306. Tollefson, A.E., Scaria, A., Hermiston, T.W., Ryerse, J.S., Wold, L.J., and Wold, W.S. (1996). The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296–2306.
Tollefson A.E.Kuppuswamy M.Shashkova E.V.Doronin K.Wold W.S.2007. Preparation and titration of CsCl-banded adenovirus stocksMethods Mol. Med.130223-235. Tollefson, A.E., Kuppuswamy, M., Shashkova, E.V., Doronin, K., and Wold, W.S. (2007). Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol. Med. 130, 223–235.
Toth K.Spencer J.F.Dhar D.Sagartz J.E.Buller R.M.Painter G.R.Wold W.S.2008. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelProc. Natl. Acad. Sci. U.S.A.1057293-7297. Toth, K., Spencer, J.F., Dhar, D., Sagartz, J.E., Buller, R.M., Painter, G.R., and Wold, W.S. (2008). Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. U.S.A. 105, 7293–7297.
Waddington S.N.McVey J.H.Bhella D.Parker A.L.Barker K.Atoda H.Pink R.Buckley S.M.Greig J.A.Denby L.Custers J.Morita T.Francischetti I.M.Monteiro R.Q.Barouch D.H.van Rooijen N.Napoli C.Havenga M.J.Nicklin S.A.Baker A.H.2008. Adenovirus serotype 5 hexon mediates liver gene transferCell132397-409. Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., Pink, R., Buckley, S.M., Greig, J.A., Denby, L., Custers, J., Morita, T., Francischetti, I.M., Monteiro, R.Q., Barouch, D.H., van Rooijen, N., Napoli, C., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397–409.
Wang Y.Wang H.Li C.Y.Yuan F.2006. Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene deliveryMol. Cancer Ther.5362-366. Wang, Y., Wang, H., Li, C.Y., and Yuan, F. (2006). Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery. Mol. Cancer Ther. 5, 362–366.
Weaver E.A.Barry M.A.2008. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responsesHum. Gene Ther.191369-1382. Weaver, E.A., and Barry, M.A. (2008). Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 19, 1369–1382.
Wisse E.Jacobs F.Topal B.Frederik P.de Geest B.2008. The size of endothelial fenestrae in human liver sinusoids: Implications for hepatocyte-directed gene transferGene Ther.151193-1199. Wisse, E., Jacobs, F., Topal, B., Frederik, P., and de Geest, B. (2008). The size of endothelial fenestrae in human liver sinusoids: Implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193–1199.
Worgall S.Wolff G.Falck-Pedersen E.Crystal R.G.1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administrationHum. Gene Ther.837-44. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R.G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37–44.
Wortmann A.Vohringer S.Engler T.Corjon S.Schirmbeck R.Reimann J.Kochanek S.Kreppel F.2008. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodiesMol. Ther.16154-162. Wortmann, A., Vohringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., Kochanek, S., and Kreppel, F. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154–162.
Yu W.Fang H.2007. Clinical trials with oncolytic adenovirus in ChinaCurr. Cancer Drug Targets7141-148. Yu, W., and Fang, H. (2007). Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141–148.
Information & Authors
Information
Published In
Copyright
Copyright 2009, Mary Ann Liebert, Inc.
History
Published in print: September 2009
Published online: 6 July 2009
Published ahead of production: 26 May 2009
Accepted: 22 May 2009
Received: 21 February 2009
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.